目的 探究贝伐珠单抗注射液联合甲磺酸阿美替尼片治疗表皮生长因子受体（EGFR）突变型Ⅳ期非小细胞肺癌的临床疗效。方法 选取2021年1月—2023年1月临汾市中心医院收治的94例EGFR突变型Ⅳ期非小细胞肺癌患者作为研究对象，按随机数字表法将所有患者分为对照组和治疗组，每组各47例。对照组患者口服甲磺酸阿美替尼片，110 mg/次，1次/d。治疗组在对照组基础上静脉滴注贝伐珠单抗注射液，15 mg/kg，每3周输注1次。两组均持续治疗12周。比较两组的临床疗效、生活质量和血清因子水平。结果 治疗后，治疗组的疾病控制率为82.98%，高于对照组的59.57%，差异有统计学意义（P＜0.05）。治疗后，两组卡氏评分表（KPS）评分、生活质量量表（SF-36）评分较治疗前均显著升高，血清正五聚蛋白3（PTX3）、趋化因子配体20（CCL20）水平较治疗前均显著降低（P＜0.05），且治疗组生活质量评分、血清因子水平较对照组更优（P＜0.05）。结论 贝伐珠单抗注射液联合甲磺酸阿美替尼片治疗EGFR突变型Ⅳ期非小细胞肺癌可有效提高疾病控制效果，显著改善患者生活质量，调节血清中PTX3、CCL20水平。

Objective To investigate the effect of Bevacizumab Injection combined with Almonertinib Mesilate Tablets in treatment of EGFR mutant stage IV non-small cell lung cancer. Methods Patients (94 cases) with EGFR mutant stage IV non-small cell lung cancer in Linfen Central Hospital from January 2021 to January 2023 were divided into control and treatment groups according to the random number table method, and each group had 47 cases. Patients in the control group were po administered with Almonertinib Mesilate Tablets, 110 mg/time, once daily. Patients in the treatment group were iv administered with Bevacizumab Injection on the basis of the control group, 15 mg/kg, infusion once every 3 weeks. Patients in two groups were treated for 12 weeks. The clinical efficacies, quality of life, and serum factor levels in two groups were compared. Results After treatment, the disease control rate of the treatment group was 82.98%, higher than 59.57% of the control group, with a statistically significant difference (P < 0.05). After treatment, KPS scores and SF-36 scores of two groups were significantly increased, while serum levels of PTX3 and CCL20 in two groups were significantly decreased (P < 0.05). And KPS score and SF-36 score of the treatment group were higher, but the serum levels of PTX3 and CCL20 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Bevacizumab Injection combined with Almonertinib Mesilate Tablets in treatment of EGFR mutant stage IV non-small cell lung cancer can effectively improve the disease control effect, significantly improve quality of life, and regulate serum levels of PTX3 and CCL20.

R979.1

中华国际科学交流基金会检验检测科技专项基金（Z2020LSXB004）